Conference reports

In-utero tenofovir-based PrEP has no effect on children’s bone mineral density

High rates of re-suppression with dolutegravir in the ADVANCE study

Bictegravir use in pregnancy: more data needed

12th IAS Conference on HIV Science (IAS 2023): further reports

IAS 2023: Update to navigating the programme and online access

IAS 2023: Metabolic and weight changes using GLP-1 agonists in people living with HIV: need for more data

IAS 2023: CHAPAS-4 supports better second-line options for children

IAS 2023: Rapporteur summary track A – basic science

IAS 2023: Rapporteur summary track C – prevention

IAS 2023: Rapporteur summary track D – social and behavioural science

12th IAS Conference on HIV Science (IAS 2023)

IAS 2023: Update to navigate the programme and online access

WHO endorses “zero” transmission risk for people with HIV with an undetectable viral load

Viral load level when suppressed <1000 predicts future rebound: 3-monthly monitoring required

ART-associated hypertension can be successfully treated in African settings

REPRIEVE study: statin benefits people living with HIV at low to moderate CVD risk

Geneva patient and other HIV cure research at IAS 2023

Guide to other HIV cure-related research at IAS 2023

Rapporteur summaries: track B clinical science

Early press conference: cure, gay circumcision, PrEP choices, mpox, and COVID-19

High rates of occult HBV in Botswana: risks from relying on HBsAg screening

Anal cancer: 1 in 5 risk of missing precancerous lesions if only HSIL are biopsied

BHIVA Annual Conference 2023 (BHIVA 2023) – final reports

No vertical HIV transmissions in the UK from women eligible for supported breastfeeding

Adverse birth outcomes with diabetes and hypertensive disorders in pregnancy

BHIVA Annual Conference 2023 (BHIVA 2023)

UK cascade data cautions UNAIDS 95:95:95 targets: re-engaging people in care

Overview of weight gain, integrase inhibitors and ART

Selected webcasts from BHIVA 2023

30th CROI (CROI 2023): final reports

Viral reservoir increases on long-term ART: new strategies for a cure

Microbiota biomarkers might predict risk of HSIL progression: succinyl-CoA and cobalamin

CROI overviews by BHIVA and IAS-USA

30th CROI (CROI 2023): further reports

Dapivirine ring safe in late pregnancy and during breastfeeding

Implications of restrictions on reproductive rights for HIV care in the USA and beyond

30th Conference on Retroviruses and OIs (CROI 2023): first reports

CROI 2023: Pipeline HIV drugs and formulations for treatment and PrEP

CROI 2023: Six-monthly ART – lenacapavir + dual bNAbs maintains undetectable viral load for 26 weeks after single doses

CROI 2023: Other lenacapavir studies – experienced and naive updates, the dosing window, HIV-2 and PrEP

CROI 2023: Similar PK profile for thigh vs gluteal CAB/RPV-LA injections: accidental intravenous injection

CROI 2023: Efficacy of N6LS monotherapy correlated with baseline factors

CROI 2023: CAB/RPV-LA levels are not reduced after switching from efavirenz

CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study

CROI 2023: Point-of-care testing for mothers and infants: results from the LIFE study

CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young adults

CROI 2023: Single dose doxycycline as PEP for STIs (DoxyPEP): five studies

CROI 2023: Severe mpox outcomes with a low CD4 count and detectable viral load: a new AIDS-defining condition?

30th Conference on Retroviruses and Opportunistic Infection (CROI 2023)

Glasgow HIV Congress (2022)

Glasgow 2022: pipeline studies with bNAbs N6LS and maturation inhibitor GSK254

Glasgow 2022: doravirine updates

Glasgow 2022: long-acting cabotegravir/rilpivirine: adverse events, implementation and PROMs

Glasgow 2022: community statement on HIV and ageing

Glasgow HIV Congress 2022

Glasgow 2022: Better re-suppression after viral rebound with DTG-based ART compared to EFV- or PI-based regimens

Glasgow 2022: Vertical transmission rate below 0.3% among women living with HIV in the UK

Glasgow 2022: Impact of islatravir on lymphocyte counts in a dose-ranging study: a post-hoc analysis

Glasgow 2022: Islatravir studies to use 0.25 mg daily dose to overcome risk of reducing CD4 and total lymphocytes

Glasgow 2022: Fostemsavir 240 week results from BRIGHTE study

Glasgow 2022: Fostemsavir: QT prolongation and drug-drug interactions

Glasgow 2022: Mpox updates on epidemiology, treatment and prevention

24th International AIDS Conference (AIDS 2022): Final report

IAS 2022: Metabolic complications of newer HIV drugs in older people

14th International Workshop on HIV & Pediatrics

Post navigation